Welcome to our dedicated page for Belite Bio SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Belite Bio, Inc (NASDAQ: BLTE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer, including Form 6‑K current reports and shelf registration materials. These documents show how Belite Bio communicates key developments around its clinical programs, financings, and regulatory interactions for its lead candidate, Tinlarebant.
Belite Bio uses Form 6‑K to furnish press releases on topics such as quarterly financial results and corporate updates, completion of enrollment in pivotal trials like the global Phase 3 PHOENIX study in geographic atrophy, and progress in the Phase 3 DRAGON program in Stargardt disease type 1 (STGD1). Other 6‑K filings describe securities purchase agreements for registered direct offerings and private placements, including details on American Depositary Shares, warrants, and registration rights agreements.
Through its filings, the company also references its shelf registration statement on Form F‑3, which supports offerings of American Depositary Shares used to fund clinical development, regulatory milestones, and commercialization preparation. While Belite Bio’s filings do not include U.S. domestic forms such as 10‑K or 10‑Q, they serve a similar role in updating investors on business progress, clinical trial status, and capital structure.
On Stock Titan, users can review Belite Bio’s SEC submissions in one place and use AI-powered summaries to interpret complex financing terms, understand the context of clinical and regulatory announcements, and see how new capital raises relate to ongoing trials in STGD1 and geographic atrophy. Filings related to equity offerings, warrants, and registration rights can help readers follow potential dilution, capital availability, and the company’s strategy for funding late-stage drug development.
Belite Bio director Chen Wan-Shan reported a compensation-related stock option award. On 3/31/2026, Chen acquired options to purchase 13,796 ordinary shares at an exercise price of 0.4386 per share, expiring on 12/22/2030.
According to the disclosure, these options stem from a grant originally issued on 12/23/2020 that vests upon meeting specific performance criteria. One such criterion was achieved on 3/31/2026, causing 13,796 additional ordinary shares to vest under the option. This is not an open-market buy or sell but a performance-based equity award.
Belite Bio’s Chief Financial Officer Hao-Yuan Chuang acquired additional vested stock options tied to performance goals. On the satisfaction of a performance criterion on March 31, 2026, an option vested as to 144,868 ordinary shares under a grant originally made on December 23, 2020.
The option has an exercise price of $0.4386 per share and an expiration date of December 22, 2030. After this vesting event, the CFO holds options exercisable for a total of 289,736 ordinary shares under this grant.
Belite Bio Chief Scientific Officer Nathan L. Mata had additional stock options vest tied to performance goals. An existing option grant from April 18, 2022 vested as to 144,868 ordinary shares on March 31, 2026 after a performance criterion was met.
The vested option covers ordinary shares at an exercise price of $6.00 per share and now totals 267,934 exercisable shares, including 123,066 shares that had previously vested. This is a compensation-related award, not an open-market stock purchase or sale.
Belite Bio director and CEO Yu-Hsin Lin reported a vesting-related stock option event tied to performance goals. On March 31, 2026, one of the performance criteria for a previously granted option was met, causing an additional 206,954 ordinary shares subject to the option to vest at an exercise price of $0.4386 per share.
This award was originally granted on December 23, 2020 and vests in installments upon meeting specific performance conditions. Following this vesting event, Lin holds options covering a total of 413,908 ordinary shares, all at the same exercise price, as part of compensation rather than an open-market trade.
Belite Bio, Inc has made its annual report on Form 20-F, which includes audited consolidated financial statements for the year ended December 31, 2025, available through its website. Shareholders can request a hard copy of the report free of charge.
The company is a clinical-stage drug developer targeting degenerative retinal diseases such as Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration. Its lead oral candidate, tinlarebant, has completed a Phase 3 trial in adolescent STGD1 and is in ongoing Phase 2/3 and Phase 3 studies.
Belite Bio, Inc., a Cayman Islands–incorporated clinical‑stage biopharmaceutical company, files its Form 20‑F for the year ended December 31, 2025. The company is highly dependent on its lead oral candidate tinlarebant (LBS‑008) for autosomal recessive Stargardt disease and geographic atrophy. Top‑line Phase 3 DRAGON results were announced in December 2025, and Belite expects to submit an NDA to the FDA in the second quarter of 2026.
The report highlights extensive development, regulatory, manufacturing, competition and reimbursement risks typical for a single‑asset biotech with no approved products. Belite recorded net losses of approximately $31.6 million, $36.1 million and $77.6 million in 2023, 2024 and 2025, respectively, with an accumulated deficit of about $185.3 million as of December 31, 2025. Net cash used in operating activities was $29.8 million, $29.2 million and $40.7 million over the same periods, and the company expects operating expenses and cash burn to continue rising as clinical and potential commercialization efforts expand. As of December 31, 2025, Belite had 39,339,960 ordinary shares outstanding and U.S. net operating loss carryforwards at several subsidiaries, which may be subject to utilization limits.
BELITE BIO, INC Chief Medical Officer Hendrik Peter Scholl filed an initial ownership report showing indirect equity positions held through Bioptima Ltd. These include stock options over 100,000, 75,000 and 40,000 ordinary shares with exercise prices of 48.6800, 54.8800 and 158.3600, expiring between 2034 and 2036, plus 35,000 ordinary shares. Footnotes describe time-based vesting, with portions of these options vesting around September 1, 2025 and January 9 in 2027, 2028 and 2029, subject to continued service.
Belite Bio, Inc. filed an initial insider ownership report for Chief Scientific Officer Nathan L. Mata, detailing his existing equity holdings. The filing shows stock options to purchase 123,066 ordinary shares at an exercise price of $6.0000 per share, expiring on April 17, 2032, which had fully vested before March 18, 2026. It also lists options on 100,000 ordinary shares at $14.4500 per share expiring on July 16, 2033, and 100,000 ordinary shares at $48.4600 per share expiring on August 28, 2034, both subject to monthly vesting schedules tied to continued service. In addition, he directly holds 16,666 American depositary shares and 16,666 ordinary shares, with each ADS representing one ordinary share.
Belite Bio, Inc. director and Chief Financial Officer Chuang Hao-Yuan filed a Form 3 disclosing his existing equity holdings in the company. The filing lists several stock options to acquire ordinary shares, including options over 144,868 shares at an exercise price of $0.4386 per share expiring on December 22, 2030, and 26,112 shares at $6.00 per share expiring on April 17, 2032.
Additional options cover 120,834 ordinary shares at $14.45, 250,000 shares at $48.46, 200,000 shares at $54.88, 40,000 shares at $77.40, 80,000 shares at $93.02, and 150,000 shares at $158.36, each with expirations between 2033 and 2036. The filing also reports direct holdings of 100,000 American depositary shares and 195,264 ordinary shares, with each ADS representing one ordinary share.
BELITE BIO, INC director Chen Xiao-Hui has filed an initial ownership report showing a modest personal stake in the company. The Form 3 indicates beneficial ownership of 400 American depositary shares as of March 18, 2026. Each American depositary share represents one ordinary share of Belite Bio, giving the director economic exposure to 400 ordinary shares. This filing does not reflect a new purchase or sale, but simply records existing holdings as the director becomes subject to insider reporting rules.